سعر ليديسبوفير 90/400 مجم 28 قرص 2022

Ledipasvir 90 mg + sofosbuvir 400 mg tablets, pack of 28, by Future Pharmaceutical Industries (FPI) > Al Rowad (Egypt); direct-acting antiviral combination for chronic hepatitis C.

• Chronic hepatitis C virus genotype 1, 4, 5 or 6 infection without cirrhosis or with compensated cirrhosis.Population: Adults and pediatric patients 3 years and olderDailyMed (U.S. National Library of Medicine)
• Chronic HCV genotype 1 infection with decompensated cirrhosis, in combination with ribavirin.Population: Adults and pediatric patients 3 years and olderDailyMed (U.S. National Library of Medicine)
• Chronic HCV genotype 1 or 4 infection in liver transplant recipients without cirrhosis or with compensated cirrhosis, in combination with ribavirin.Population: Adults and pediatric patients 3 years and olderDailyMed (U.S. National Library of Medicine)

• Most common adverse reactions: fatigue, headache and asthenia.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• No contraindications of its own; when used with ribavirin, all ribavirin contraindications apply.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Boxed warning: risk of hepatitis B virus reactivation in HCV/HBV coinfected patients, sometimes resulting in fulminant hepatitis, hepatic failure and death; test all patients for HBsAg and anti-HBc before starting and monitor during and after treatment.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Serious symptomatic bradycardia when coadministered with amiodarone, particularly with beta-blockers or underlying cardiac disease; coadministration is not recommended.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• AmiodaroneSerious symptomatic bradycardia; coadministration not recommended (cardiac monitoring if no alternative).DailyMed (U.S. National Library of Medicine)
• AntacidsReduce ledipasvir absorption; separate administration by 4 hours.DailyMed (U.S. National Library of Medicine)
• H2-receptor antagonistsMay be given simultaneously or 12 hours apart at doses not exceeding the equivalent of famotidine 40 mg twice daily.DailyMed (U.S. National Library of Medicine)

• No adequate human data are available to establish whether HARVONI poses a risk to pregnancy outcomes; no adverse developmental effects were observed in animal studies with ledipasvir or sofosbuvir. If used with ribavirin, ribavirin pregnancy contraindications apply.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• It is not known whether ledipasvir, sofosbuvir or their metabolites are present in human milk; weigh the benefits of breastfeeding against the mother's clinical need.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Ledipasvir: Inhibits the HCV NS5A protein, which is required for viral replication (US label).
• Sofosbuvir: Nucleotide prodrug metabolised to an active uridine analogue triphosphate that is incorporated into HCV RNA by the NS5B RNA-dependent RNA polymerase and acts as a chain terminator (US label).